1 Sanchez-Fructuoso AI, Marques M, Conesa J, et al. Use of different immunosuppressive strategies in recipients of kidneys from nonheart-beating donors. Transpl Int 2005; 18: 596.
10.1111/j.1432-2277.2005.00100.x
CAS PubMed Web of Science® Google Scholar
2 Wilson CH, Brook NR, Gok MA, et al. Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. Br J Surg 2005; 92: 6.
10.1002/bjs.4976
Web of Science® Google Scholar
3 Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657.
10.1097/01.TP.0000053198.99206.E6
CAS PubMed Web of Science® Google Scholar
4 Meier-Kriesche HU, Arndorfer JA, Kaplan B. Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 2002; 13: 769.
PubMed Web of Science® Google Scholar
5 Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486.
10.1111/j.1523-1755.2004.761_3.x
PubMed Web of Science® Google Scholar
6 Wilson CH, Stansby G, Haswell M, Cunningham AC, Talbot D. Evaluation of eight preservation solutions for endothelial in situ preservation. Transplantation 2004; 78: 1008.
10.1097/01.TP.0000135465.00738.ED
CAS PubMed Web of Science® Google Scholar

Citing Literature

September 2005

Page 1116

Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury